Author
Listed:
- María José Lista
(Institut National de la Santé et de la Recherche Médicale UMR1078; Etablissement Français du Sang (EFS) Bretagne; CHRU Brest, Hôpital Morvan, Laboratoire de Génétique Moléculaire
Université de Bretagne Occidentale, Faculté de Médecine et des Sciences de la Santé)
- Rodrigo Prado Martins
(Cibles Thérapeutiques, Institut National de la Santé et de la Recherche Médicale UMR1162, Institut de Génétique Moléculaire)
- Olivier Billant
(Institut National de la Santé et de la Recherche Médicale UMR1078; Etablissement Français du Sang (EFS) Bretagne; CHRU Brest, Hôpital Morvan, Laboratoire de Génétique Moléculaire
Université de Bretagne Occidentale, Faculté de Médecine et des Sciences de la Santé)
- Marie-Astrid Contesse
(Institut National de la Santé et de la Recherche Médicale UMR1078; Etablissement Français du Sang (EFS) Bretagne; CHRU Brest, Hôpital Morvan, Laboratoire de Génétique Moléculaire
Université de Bretagne Occidentale, Faculté de Médecine et des Sciences de la Santé)
- Sarah Findakly
(Cibles Thérapeutiques, Institut National de la Santé et de la Recherche Médicale UMR1162, Institut de Génétique Moléculaire)
- Pierre Pochard
(Inserm UMR 1227, Lymphocytes B et Autoimmunité; CHRU Brest, Hôpital Morvan, Laboratoire d’Immunologie
Université de Bretagne Occidentale)
- Chrysoula Daskalogianni
(Cibles Thérapeutiques, Institut National de la Santé et de la Recherche Médicale UMR1162, Institut de Génétique Moléculaire)
- Claire Beauvineau
(Chemistry, Modelling and Imaging for Biology, CNRS UMR9187 - Inserm U1196, Institut Curie, Université Paris-Sud)
- Corinne Guetta
(Chemistry, Modelling and Imaging for Biology, CNRS UMR9187 - Inserm U1196, Institut Curie, Université Paris-Sud)
- Christophe Jamin
(Inserm UMR 1227, Lymphocytes B et Autoimmunité; CHRU Brest, Hôpital Morvan, Laboratoire d’Immunologie
Université de Bretagne Occidentale)
- Marie-Paule Teulade-Fichou
(Chemistry, Modelling and Imaging for Biology, CNRS UMR9187 - Inserm U1196, Institut Curie, Université Paris-Sud)
- Robin Fåhraeus
(Cibles Thérapeutiques, Institut National de la Santé et de la Recherche Médicale UMR1162, Institut de Génétique Moléculaire)
- Cécile Voisset
(Institut National de la Santé et de la Recherche Médicale UMR1078; Etablissement Français du Sang (EFS) Bretagne; CHRU Brest, Hôpital Morvan, Laboratoire de Génétique Moléculaire
Université de Bretagne Occidentale, Faculté de Médecine et des Sciences de la Santé)
- Marc Blondel
(Institut National de la Santé et de la Recherche Médicale UMR1078; Etablissement Français du Sang (EFS) Bretagne; CHRU Brest, Hôpital Morvan, Laboratoire de Génétique Moléculaire
Université de Bretagne Occidentale, Faculté de Médecine et des Sciences de la Santé)
Abstract
The oncogenic Epstein-Barr virus (EBV) evades the immune system but has an Achilles heel: its genome maintenance protein EBNA1, which is essential for viral genome maintenance but highly antigenic. EBV has seemingly evolved a system in which the mRNA sequence encoding the glycine-alanine repeats (GAr) of the EBNA1 protein limits its expression to the minimal level necessary for function while minimizing immune recognition. Here, we identify nucleolin (NCL) as a host factor required for this process via a direct interaction with G-quadruplexes formed in GAr-encoding mRNA sequence. Overexpression of NCL enhances GAr-based inhibition of EBNA1 protein expression, whereas its downregulation relieves the suppression of both expression and antigen presentation. Moreover, the G-quadruplex ligand PhenDC3 prevents NCL binding to EBNA1 mRNA and reverses GAr-mediated repression of EBNA1 expression and antigen presentation. Hence the NCL-EBNA1 mRNA interaction is a relevant therapeutic target to trigger an immune response against EBV-carrying cancers.
Suggested Citation
María José Lista & Rodrigo Prado Martins & Olivier Billant & Marie-Astrid Contesse & Sarah Findakly & Pierre Pochard & Chrysoula Daskalogianni & Claire Beauvineau & Corinne Guetta & Christophe Jamin &, 2017.
"Nucleolin directly mediates Epstein-Barr virus immune evasion through binding to G-quadruplexes of EBNA1 mRNA,"
Nature Communications, Nature, vol. 8(1), pages 1-13, December.
Handle:
RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms16043
DOI: 10.1038/ncomms16043
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms16043. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.